Sense Medicine has raised a total of $65 million in series B financing, which the company will use to bring its Veros point-of-care COVID-19 test to the U.S. market.
The Veros COVID-19 test is an instrument-free, single-use, rapid, point-of-care molecular diagnostic testing platform that produces results within 15 minutes.
The company has submitted an emergency use authorization (EUA) to the U.S. Food and Drug Administration (FDA) for marketing clearance for the test. Sense hopes to make the test commercially available in 2022.
